---
schema_version: "secwatch.filing_event.v1"
accession: "0001082554-22-000028"
form_type: "8-K"
ticker: "UTHR"
cik: "0001082554"
company_name: "UNITED THERAPEUTICS Corp"
filed_at: "2022-11-02T23:59:59+00:00"
generated_at: "2026-06-22T11:50:03.863771+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# United Therapeutics Q3 revenue $516M (+16% YoY); net income $239M (+47%)

## Summary
- Net income per diluted share $4.91; Tyvaso revenues $257.7M (+57% YoY) driven by Tyvaso DPI launch.
- Tyvaso achieved $1B annual run-rate; management targets 6,000 patients on Tyvaso by year-end.
- R&D expense $66.1M (-17% YoY) due to fair value adjustments; PERFECT study discontinued per DSMC.
- TETON 2 study of Tyvaso in IPF enrolled first patient October 2022; TETON 1 enrollment ongoing.
- Remunity Pump launched patient-filled version in September 2022 for monthly cassette shipments.

## SEC filing metadata
- accession: 0001082554-22-000028
- form_type: 8-K
- ticker: UTHR
- cik: 0001082554
- company_name: UNITED THERAPEUTICS Corp
- filed_at: 2022-11-02T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1082554/000108255422000028/0001082554-22-000028-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1082554/000108255422000028/uthr-20221102.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001082554-22-000028
- JSON: https://secwatch.observer/filing/0001082554-22-000028.json
- Plain text: https://secwatch.observer/filing/0001082554-22-000028.txt

## Key facts
- Earnings Releases
  UNITED THERAPEUTICS Corp reported the quarter ended September 30, 2022 results: revenue $516.0 million, net income $239.3, EPS $4.91.
  - Period: the quarter ended September 30, 2022
  - Revenue: $516.0 million
  - Net income: $239.3
  - EPS: $4.91
  - Result: reported results
  source text: benefit corporation, today announced its financial results for the quarter ended September 30, 2022. Total revenues in the third quarter of 2022 grew 16% year-over-year to $516.0 million, compared to $444.7 million in the third quarter of 2021. “We are thrilled to report the highest quarterly revenue in our history,” said Martine Rothblatt, Ph.D. , Chairperson
  evidence_url: https://www.sec.gov/Archives/edgar/data/1082554/000108255422000028/0001082554-22-000028-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.